LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritis
NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults […]
Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […]
New Approach to Treating Lupus Nephritis
February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […]
Lupus Research Alliance Announces Recipients of the Lupus Mechanisms and Targets Award
New York, NY, February 28. The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE). The LMTA provides investigators up to $600,000 […]
Join LRA March 11 to Learn What’s New in Lupus Nephritis
What’s New in Lupus Nephritis? A Research & Treatment Update A Learn from Lupus Webcast Lupus nephritis is a common and dangerous complication of lupus marked by inflammation that can lead to damage and possible failure of the kidney. While up to half of people with lupus develop lupus nephritis, a new survey by the Lupus […]
Study Shows Kidney Transplant Improves Lupus Nephritis Survival
January 21, 2019 A study just published in Annals of Internal Medicine showed that kidney transplantation reduced deaths due to lupus nephritis — kidney inflammation caused by lupus. Up to 60 percent of people with SLE are diagnosed with lupus nephritis, which can lead to significant illness and even death. According to the National Institute of Diabetes […]
New Phase 3 Study Shows Positive Results for Benlysta® in Lupus Nephritis
December 17, 2019 The Lupus Research Alliance is thrilled to share exciting news from GSK that Benlysta (belimumab) demonstrated positive clinical trial results in treating lupus nephritis (LN), a common complication of lupus causing inflammation of the kidneys that can result in end-stage kidney disease. Called BLISS-LN, this Phase 3 trial is the largest one […]
Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback
April 20, 2021 At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an independent panel voted unanimously that both belimumab (Benlysta) and voclosporin (Lupkynis), newly approved to treat lupus nephritis, provide a health benefit over standard therapy alone. ICER’s policy recommendations for the use of these two medications […]
LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting
Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […]
Great News for Lupus Nephritis Treatment: Itolizumab Fast-Tracked by FDA
December 10, 2019 The Lupus Research Alliance (LRA) is pleased to share that a potential new treatment in development by Equillium, Inc. for lupus nephritis, itolizumab, was granted Fast Track designation by the U.S. Food and Drug Administration. As defined by the FDA, this designation is “designed to facilitate the development, and expedite the review […]